Advertisement

Quantifying the relationship between age at diagnosis and breast cancer-specific mortality

  • Helen M. Johnson
  • William Irish
  • Mahvish Muzaffar
  • Nasreen A. Vohra
  • Jan H. WongEmail author
Epidemiology
  • 4 Downloads

Abstract

Purpose

The relationship between age at diagnosis and breast cancer-specific mortality (BCSM) is unclear. The aim of this study was to examine the nature of this relationship using rigorous statistical methodology.

Methods

A historical cohort study of adult women with invasive breast cancer in the SEER database from 2000 to 2015 was conducted. Multivariable Cox’s cause-specific hazards model was used to evaluate the association of age at diagnosis with risk of BCSM. Functional relationship of age was assessed using cumulative sums of Martingale residuals and the Kolmogorov-type supremum test.

Results

A total of 206,332 women were eligible for study. Mean age at diagnosis was 59.7 ± 13.8 years. Median follow-up was 80 months. During the study period, 21,771 women (10.6%) died from breast cancer and 18,566 (9.0%) died from other causes. Cumulative incidence of BCSM at 120 months post-diagnosis was 14.4% (95% CI 14.2–14.6%). Age was found to be quadratically related to the risk of BCSM (p < 0.001), with a nadir at 45 years of age. The final Cox model suggests that a 30-year-old woman has approximately the same adjusted BCSM risk (HR 1.187, 95% CI 1.187–1.188) as a 60-year-old woman (HR 1.174, 95% CI 1.174–1.175).

Conclusions

Women diagnosed with breast cancer at the extremes of age suffer disproportionate rates of cancer-specific mortality. The relationship between age at diagnosis and adjusted risk of BCSM is complex, consistent with a quadratic function. With the growing appreciation for breast cancer as a heterogeneous disease, it is essential to accurately address age as a prognostic risk factor in predictive models.

Keywords

Breast cancer Mortality Differential mortality Age groups Age distribution Statistical model 

Abbreviations

AIC

Akaike information criterion

AJCC

American Joint Committee on Cancer

BCSM

Breast cancer-specific mortality

CI

Confidence interval

SD

Standard deviation

ER

Estrogen receptor

HER2

Human epidermal growth factor receptor

HR

Hazard ratio

PR

Progesterone receptor

SEER

Surveillance, epidemiology, and end results

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

As this study is based on a publicly available database without identifying patient information, informed consent was not needed.

Supplementary material

10549_2019_5353_MOESM1_ESM.tiff (199.5 mb)
Supplementary material 1 (TIFF 204308 kb). Supplemental Fig. 1. Subgroup analysis (2010–2015). Observed cumulative Martingale residual plot against age at diagnosis with 20 simulated realizations. This plot is used to determine the functional form of age on the risk of breast cancer-specific mortality
10549_2019_5353_MOESM2_ESM.tiff (92.2 mb)
Supplementary material 2 (TIFF 94405 kb). Supplemental Fig. 2. Subgroup analysis (2010–2015). Akaike information criterion (AIC) for candidate Cox models. The model with the smallest value is considered the best model
10549_2019_5353_MOESM3_ESM.tiff (137.3 mb)
Supplementary material 3 (TIFF 140634 kb). Supplemental Fig. 3. Subgroup analysis (2010–2015). The plot of the hazard ratio for increasing age based on the fit of the Cox model with age at diagnosis included as a quadratic term. The superimposed histogram demonstrates that the age distribution of is approximately normal
10549_2019_5353_MOESM4_ESM.tiff (91.7 mb)
Supplementary material 4 (TIFF 93898 kb). Supplemental Fig. 4. Subgroup analysis (2010–2015). Risk of breast cancer-specific mortality over time with age included as a time-dependent covariate

References

  1. 1.
    Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A, Marcos-Gragera R, Stiller C, Azevedo e Silva G, Chen WQ, Ogunbiyi OJ, Rachet B, Soeberg MJ, You H, Matsuda T, Bielska-Lasota M, Storm H, Tucker TC, Coleman MP, Group CW (2015) Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 385(9972):977–1010.  https://doi.org/10.1016/S0140-6736(14)62038-9 CrossRefGoogle Scholar
  2. 2.
    Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, Mariotto A, Lake AJ, Wilson R, Sherman RL, Anderson RN, Henley SJ, Kohler BA, Penberthy L, Feuer EJ, Weir HK (2017) Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival. J Natl Cancer Inst.  https://doi.org/10.1093/jnci/djx030 Google Scholar
  3. 3.
    Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ, Collaborators CIaSMNC (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353(17):1784–1792.  https://doi.org/10.1056/NEJMoa050518 CrossRefGoogle Scholar
  4. 4.
    Siegel RL, Miller KD (2019) Jemal A (2019) Cancer statistics. CA Cancer J Clin 69(1):7–34.  https://doi.org/10.3322/caac.21551 CrossRefGoogle Scholar
  5. 5.
    Kohler BA, Sherman RL, Howlader N, Jemal A, Ryerson AB, Henry KA, Boscoe FP, Cronin KA, Lake A, Noone AM, Henley SJ, Eheman CR, Anderson RN, Penberthy L (2015) Annual Report to the Nation on the Status of Cancer, 1975–2011, Featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst 107(6):48.  https://doi.org/10.1093/jnci/djv048 CrossRefGoogle Scholar
  6. 6.
    Verdial FC, Etzioni R, Duggan C, Anderson BO (2017) Demographic changes in breast cancer incidence, stage at diagnosis and age associated with population-based mammographic screening. J Surg Oncol 115(5):517–522.  https://doi.org/10.1002/jso.24579 CrossRefGoogle Scholar
  7. 7.
    Zhang X, Yang J, Cai H, Ye Y (2018) Young age is an independent adverse prognostic factor in early stage breast cancer: a population-based study. Cancer Manag Res 10:4005–4018.  https://doi.org/10.2147/CMAR.S167363 CrossRefGoogle Scholar
  8. 8.
    Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA (2009) Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg 208(3):341–347.  https://doi.org/10.1016/j.jamcollsurg.2008.12.001 CrossRefGoogle Scholar
  9. 9.
    de la Rochefordiere A, Asselain B, Campana F, Scholl SM, Fenton J, Vilcoq JR, Durand JC, Pouillart P, Magdelenat H, Fourquet A (1993) Age as prognostic factor in premenopausal breast carcinoma. Lancet 341(8852):1039–1043CrossRefGoogle Scholar
  10. 10.
    Jayasinghe UW, Taylor R, Boyages J (2005) Is age at diagnosis an independent prognostic factor for survival following breast cancer? ANZ J Surg 75(9):762–767.  https://doi.org/10.1111/j.1445-2197.2005.03515.x CrossRefGoogle Scholar
  11. 11.
    Balabram D, Turra CM, Gobbi H (2015) Association between age and survival in a cohort of Brazilian patients with operable breast cancer. Cad Saude Publica 31(8):1732–1742.  https://doi.org/10.1590/0102-311X00114214 CrossRefGoogle Scholar
  12. 12.
    Roder DM, de Silva P, Zorbas HM, Kollias J, Malycha PL, Pyke CM, Campbell ID (2012) Age effects on survival from early breast cancer in clinical settings in Australia. ANZ J Surg 82(7–8):524–528.  https://doi.org/10.1111/j.1445-2197.2012.06114.x CrossRefGoogle Scholar
  13. 13.
    Brandt J, Garne JP, Tengrup I, Manjer J (2015) Age at diagnosis in relation to survival following breast cancer: a cohort study. World J Surg Oncol 13:33.  https://doi.org/10.1186/s12957-014-0429-x CrossRefGoogle Scholar
  14. 14.
    Chen HL, Zhou MQ, Tian W, Meng KX, He HF (2016) Effect of age on breast cancer patient prognoses: a population-based study using the SEER 18 database. PLoS ONE 11(10):e0165409.  https://doi.org/10.1371/journal.pone.0165409 CrossRefGoogle Scholar
  15. 15.
    Schonberg MA, Marcantonio ER, Li D, Silliman RA, Ngo L, McCarthy EP (2010) Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. J Clin Oncol 28(12):2038–2045.  https://doi.org/10.1200/JCO.2009.25.9796 CrossRefGoogle Scholar
  16. 16.
    Lodi M, Scheer L, Reix N, Heitz D, Carin AJ, Thiébaut N, Neuberger K, Tomasetto C, Mathelin C (2017) Breast cancer in elderly women and altered clinico-pathological characteristics: a systematic review. Breast Cancer Res Treat 166(3):657–668.  https://doi.org/10.1007/s10549-017-4448-5 CrossRefGoogle Scholar
  17. 17.
    National Cancer Institute. Overview of the SEER Program. https://seer.cancer.gov/about/overview.html. Accessed 21 Mar 2019
  18. 18.
    Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER 18 Regs Custom Data (with additional treatment fields), Nov 2017 Sub (1973-2015 varying)—Linked to County Attributes—Total U.S., 1969-2016 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2018, based on the November 2017 submission. Accessed 24 August 2018
  19. 19.
    National Cancer Institute. Breast Subtype (2010 +). https://seer.cancer.gov/seerstat/databases/ssf/breast-subtype.html. Accessed 21, Mar 2019
  20. 20.
    Lin DY, Wei LJ, Ying Z (1993) Checking the cox model with cumulative sums of martingale-based residuals. Biometrika 80(3):557–572.  https://doi.org/10.2307/2337177 CrossRefGoogle Scholar
  21. 21.
    Rosenberg J, Chia YL, Plevritis S (2005) The effect of age, race, tumor size, tumor grade, and disease stage on invasive ductal breast cancer survival in the US SEER database. Breast Cancer Res Treat 89(1):47–54.  https://doi.org/10.1007/s10549-004-1470-1 CrossRefGoogle Scholar
  22. 22.
    Tai P, Cserni G, Van De Steene J, Vlastos G, Voordeckers M, Royce M, Lee SJ, Vinh-Hung V, Storme G (2005) Modeling the effect of age in T1-2 breast cancer using the SEER database. BMC Cancer 5:130.  https://doi.org/10.1186/1471-2407-5-130 CrossRefGoogle Scholar
  23. 23.
    Hortobagyi GNCJ, Edge SB et al (2018) Breast. In: Amin MB, Edge S, Greene F et al (eds) AJCC Cancer Staging Manual, 8th edn. Springer, New YorkGoogle Scholar
  24. 24.
    Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H (2009) Breast cancer in young women: poor survival despite intensive treatment. PLoS ONE 4(11):e7695.  https://doi.org/10.1371/journal.pone.0007695 CrossRefGoogle Scholar
  25. 25.
    Klauber-DeMore N (2005) Tumor biology of breast cancer in young women. Breast Dis 23:9–15CrossRefGoogle Scholar
  26. 26.
    Noone AM, Lund JL, Mariotto A, Cronin K, McNeel T, Deapen D, Warren JL (2016) Comparison of SEER Treatment data with medicare claims. Med Care 54(9):e55–64.  https://doi.org/10.1097/MLR.0000000000000073 CrossRefGoogle Scholar
  27. 27.
    Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, Nevins JR, Potti A, Blackwell KL (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26(20):3324–3330.  https://doi.org/10.1200/JCO.2007.14.2471 CrossRefGoogle Scholar
  28. 28.
    Wang MX, Ren JT, Tang LY, Ren ZF (2018) Molecular features in young vs elderly breast cancer patients and the impacts on survival disparities by age at diagnosis. Cancer Med 1:1–10.  https://doi.org/10.1002/cam4.1544 Google Scholar
  29. 29.
    Borges VF, Schedin PJ (2012) Pregnancy-associated breast cancer: an entity needing refinement of the definition. Cancer 118(13):3226–3228.  https://doi.org/10.1002/cncr.26643 CrossRefGoogle Scholar
  30. 30.
    Callihan EB, Gao D, Jindal S, Lyons TR, Manthey E, Edgerton S, Urquhart A, Schedin P, Borges VF (2013) Postpartum diagnosis demonstrates a high risk for metastasis and merits an expanded definition of pregnancy-associated breast cancer. Breast Cancer Res Treat 138(2):549–559.  https://doi.org/10.1007/s10549-013-2437-x CrossRefGoogle Scholar
  31. 31.
    Johansson AL, Andersson TM, Hsieh CC, Cnattingius S, Lambe M (2011) Increased mortality in women with breast cancer detected during pregnancy and different periods postpartum. Cancer Epidemiol Biomarkers Prev 20(9):1865–1872.  https://doi.org/10.1158/1055-9965.EPI-11-0515 CrossRefGoogle Scholar
  32. 32.
    Varghese F, Wong J (2018) Breast Cancer in the Elderly. Surg Clin North Am 98(4):819–833.  https://doi.org/10.1016/j.suc.2018.04.002 CrossRefGoogle Scholar
  33. 33.
    Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, Muss HB, Smith BL, Hudis CA, Winer EP, Wood WC (2013) Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 31(19):2382–2387.  https://doi.org/10.1200/JCO.2012.45.2615 CrossRefGoogle Scholar
  34. 34.
    Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM, Investigators PI (2015) Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol 16(3):266–273.  https://doi.org/10.1016/S1470-2045(14)71221-5 CrossRefGoogle Scholar
  35. 35.
    Society of Surgical Oncology. Choosing Wisely: Five Things that Patients and Physicians Should Question. (2016). http://www.choosingwisely.org/societies/society-of-surgical-oncology/. Accessed 7 Apr 2019
  36. 36.
    Mamtani A, Gonzalez JJ, Neo DT, Friedman RS, Recht A, Hacker MR, Sharma R (2018) Treatment strategies in octogenarians with early-stage high-risk breast cancer. Ann Surg Oncol 25(6):1495–1501.  https://doi.org/10.1245/s10434-018-6350-8 CrossRefGoogle Scholar
  37. 37.
    Gajdos C, Tartter PI, Bleiweiss IJ, Lopchinsky RA, Bernstein JL (2001) The consequence of undertreating breast cancer in the elderly. J Am Coll Surg 192(6):698–707CrossRefGoogle Scholar
  38. 38.
    Yood MU, Owusu C, Buist DS, Geiger AM, Field TS, Thwin SS, Lash TL, Prout MN, Wei F, Quinn VP, Frost FJ, Silliman RA (2008) Mortality impact of less-than-standard therapy in older breast cancer patients. J Am Coll Surg 206(1):66–75.  https://doi.org/10.1016/j.jamcollsurg.2007.07.015 CrossRefGoogle Scholar
  39. 39.
    Bouchardy C, Rapiti E, Fioretta G, Laissue P, Neyroud-Caspar I, Schäfer P, Kurtz J, Sappino AP, Vlastos G (2003) Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 21(19):3580–3587.  https://doi.org/10.1200/JCO.2003.02.046 CrossRefGoogle Scholar
  40. 40.
    Rao VS, Jameel JK, Mahapatra TK, McManus PL, Fox JN, Drew PJ (2007) Surgery is associated with lower morbidity and longer survival in elderly breast cancer patients over 80. Breast J 13(4):368–373.  https://doi.org/10.1111/j.1524-4741.2007.00444.x CrossRefGoogle Scholar
  41. 41.
    Tamirisa N, Thomas SM, Fayanju OM, Greenup RA, Rosenberger LH, Hyslop T, Hwang ES, Plichta JK (2018) Axillary nodal evaluation in elderly breast cancer patients: potential effects on treatment decisions and survival. Ann Surg Oncol 25(10):2890–2898.  https://doi.org/10.1245/s10434-018-6595-2 CrossRefGoogle Scholar
  42. 42.
    Azim HA, Nguyen B, Brohée S, Zoppoli G, Sotiriou C (2015) Genomic aberrations in young and elderly breast cancer patients. BMC Med 13:266.  https://doi.org/10.1186/s12916-015-0504-3 CrossRefGoogle Scholar
  43. 43.
    Adami HO, Malker B, Holmberg L, Persson I, Stone B (1986) The relation between survival and age at diagnosis in breast cancer. N Engl J Med 315(9):559–563.  https://doi.org/10.1056/NEJM198608283150906 CrossRefGoogle Scholar
  44. 44.
    Cluze C, Colonna M, Remontet L, Poncet F, Sellier E, Seigneurin A, Delafosse P, Bossard N (2009) Analysis of the effect of age on the prognosis of breast cancer. Breast Cancer Res Treat 117(1):121–129.  https://doi.org/10.1007/s10549-008-0222-z CrossRefGoogle Scholar
  45. 45.
    Forsare C, Bak M, Falck AK, Grabau D, Killander F, Malmström P, Rydén L, Stål O, Sundqvist M, Bendahl PO, Fernö M (2018) Non-linear transformations of age at diagnosis, tumor size, and number of positive lymph nodes in prediction of clinical outcome in breast cancer. BMC Cancer 18(1):1226.  https://doi.org/10.1186/s12885-018-5123-x CrossRefGoogle Scholar
  46. 46.
    Haddad RI, Nasr C, Bischoff L, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Goldner W, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McIver B, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sippel R, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Johnson-Chilla A, Hoffmann KG, Gurski LA (2018) NCCN guidelines insights: Thyroid carcinoma, Version 2.2018. J Natl Compr Canc Netw 16(12):1429–1440.  https://doi.org/10.6004/jnccn.2018.0089 CrossRefGoogle Scholar
  47. 47.
    Wishart GC, Bajdik CD, Dicks E, Provenzano E, Schmidt MK, Sherman M, Greenberg DC, Green AR, Gelmon KA, Kosma VM, Olson JE, Beckmann MW, Winqvist R, Cross SS, Severi G, Huntsman D, Pylkäs K, Ellis I, Nielsen TO, Giles G, Blomqvist C, Fasching PA, Couch FJ, Rakha E, Foulkes WD, Blows FM, Bégin LR, van’t Veer LJ, Southey M, Nevanlinna H, Mannermaa A, Cox A, Cheang M, Baglietto L, Caldas C, Garcia-Closas M, Pharoah PD (2012) PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer 107(5):800–807.  https://doi.org/10.1038/bjc.2012.338 CrossRefGoogle Scholar
  48. 48.
    Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, Davis GJ, Chia SK, Gelmon KA (2005) Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23(12):2716–2725.  https://doi.org/10.1200/JCO.2005.06.178 CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Helen M. Johnson
    • 1
  • William Irish
    • 1
  • Mahvish Muzaffar
    • 2
  • Nasreen A. Vohra
    • 1
  • Jan H. Wong
    • 1
    Email author
  1. 1.Division of Surgical Oncology, Department of SurgeryEast Carolina University Brody School of MedicineGreenvilleUSA
  2. 2.Department of Medicine, Division of Hematology/OncologyEast Carolina University Brody School of MedicineGreenvilleUSA

Personalised recommendations